Examining the relationship between pre-treatment anhedonia and treatment outcomes in individuals with anxiety or depression: A systematic review.

J Affect DisordNov 21, 2025 (epub)
Clinical ResearchPsychiatryOpen access

Madeleine Rassaby, Isabella G Spaulding, Murray B Stein et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined whether pre-treatment anhedonia or lower reward sensitivity was associated with outcomes of psychotherapy, pharmacotherapy, or neuromodulation in people with anxiety or unipolar depressive disorders. Among 28 included articles, nine (32.1 %) linked greater anhedonia or lower reward sensitivity to worse response; four (14.3 %) linked it to better outcomes, eleven (39.3 %) reported mixed findings, and four (14.3 %) found no significant relationship. The authors concluded that inconsistent results do not support definitive conclusions about anhedonia as a treatment predictor.

Key findings

  • Nine of 28 articles (32.1 %) associated higher anhedonia or lower reward sensitivity with worse treatment response.
  • Four studies (14.3 %) linked anhedonia or lower reward sensitivity to better outcomes; eleven (39.3 %) reported mixed results.
  • Four studies (14.3 %) found no significant relationship between pre-treatment anhedonia or reward sensitivity and treatment outcomes.

Why it matters

Anhedonia is a potential predictor that could help explain variation in response to treatments for anxiety and depression. However, the review found results pointing in different directions, so its clinical value remains uncertain. Clarifying whether anhedonia, its components, or reward-sensitivity measures relate to outcomes may help future research identify more informative predictors.

What to keep in mind

Findings were heterogeneous across treatments, designs, measures, and outcomes. Most studies were secondary analyses and were often inadequately powered, limiting definitive conclusions.

Source

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.